Europe Cannabidiol Key Players and their Developments

Top Companies in the Europe Cannabidiol Market & Their Offerings

What are the Recent Developments in the Europe Cannabidiol Market? 

• In March 2026, GVB Biopharma achieved significant growth in its cannabinoid business, reflecting strong expansion in the global supply chain. The company recorded sales of more than 12,000 kg of CBD, CBG, and CBN isolates in just one month, equivalent to over 1 billion 10 mg doses. Overall, its sales for the first quarter of 2026 surpassed 30,000 kg, highlighting rapid production scale-up and rising demand.
• In March 2026, Organigram Global Inc. strengthened its presence in Europe by focusing on acquisition-driven expansion strategies. The company aimed to enter and grow in key markets such as Germany, improving its distribution network and increasing overall market reach across the region. This move supports its broader goal of enhancing penetration in the European cannabis and CBD industry.

Supply Chain Analysis

R&D

• Europe’s cannabidiol (CBD) R&D ecosystem is rapidly expanding, driven by clearer regulations and strong pharmaceutical innovation. Current research focuses on improving CBD bioavailability through advanced nano-delivery systems, strengthening EU-GMP compliant cultivation practices, and meeting strict Novel Food and medical approval standards in key markets like Germany and Poland.
• Key players: Tilray, Canopy Growth Corporation, Aurora Cannabis, Jazz Pharmaceuticals, and Organigram Holdings Inc.

Clinical Trials

• Clinical trials for cannabidiol (CBD) in Europe are increasingly focused on evaluating its effectiveness in treating pain, mental health disorders, and rare neurological diseases. Although CBD-based medicines like Epidiolex are already approved for certain forms of childhood epilepsy, ongoing studies are exploring wider therapeutic uses of high-quality, standardized CBD formulations.
• Key players: Jazz Pharmaceuticals, GW Pharmaceuticals (now part of Jazz), Tilray

Patient Support and Services

• Access to cannabidiol (CBD) in Europe is strictly controlled and varies by country. Prescription-based medical CBD, such as Epidyolex, is approved for limited conditions like severe epilepsy, while broader use for wellness or chronic conditions is available through regulated medical cannabis programs or hemp-derived OTC CBD products in select markets. Patients typically obtain these through licensed clinics, pharmacies, and approved healthcare channels under national regulations.
• Key players: Jazz Pharmaceuticals, Canopy Growth Corporation, Tilray, and Aurora Cannabis.

Market Growth

The Europe cannabidiol market size was estimated at USD 415.6 million in 2025 and is predicted to increase from USD 481.39 million in 2026 to approximately USD 1806.7 million by 2035, expanding at a CAGR of 15.83% from 2026 to 2035.